Rapidly growing number of people, suffering from neurological disorders coupled with rise in geriatric population globally has fueled the demand efficient and effective treatment measures. These factors affected positively and dragged the attraction of key players to invest in research and development of intravenous immunoglobulin for increasing effectiveness of the treatments of off-label indications. Additionally, rising awareness about advent of technologies are driving growth of the global intravenous immunoglobulin market.
North America to be Dominant Region in Coming Years
Regionally, North America dominated the global intravenous immunoglobulin market in 2017 owing to presence of superior health care infrastructure coupled with presence of reimbursement policies. Additionally, the geriatric population in the region has been growing and accounted for almost 13% of total population in 2017 and is estimated to increase at a rate of 3% per year. Europe stood on the second leading position owing to highest percentage of geriatric population of almost 25%. In addition, increasing geriatric population is estimated to continue in the coming years and thus by 2050, the number will be 2.1 billion. The elderly population is largely susceptible for chronic inflammatory demyelinating polyneuropathy (CIDP) and thus resulting to high demand for intravenous immunoglobulin (IVIG).
Asia Pacific to Witness Most Lucrative Opportunities in Next Few Years
The intravenous immunoglobulin market present across Europe is likely to witness strong growth owing to surge in inpatient population coupled with rise in consumers of intravenous immunoglobulin especially the hospitals and clinics. The emerging countries across Asia Pacific such as China and India are estimated to witness most promising growth in coming years owing to large underserved patient population in the region. In addition to all these factors, extensive healthcare development and continuous infrastructural improvement coupled with robust investment in the research and development in healthcare is anticipated to offer most lucrative opportunities in the global intravenous immunoglobulin market.
Request Multiple Chapters
This post was originally published on The Market Plan